{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Morphotek", "query": { "sponsor": "Morphotek" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Morphotek&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T23:09:20.999Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01018563", "title": "An Open Label Extension Study of the Efficacy of MORAb-003", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer" ], "interventions": [ { "name": "MORAb-003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2010-01-13", "completion_date": "2013-03-05", "has_results": true, "last_update_posted_date": "2021-12-08", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 2, "location_summary": "Chula Vista, California • San Antonio, Texas", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01018563" }, { "nct_id": "NCT01218516", "title": "A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Lung" ], "interventions": [ { "name": "Farletuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2011-06-27", "completion_date": "2013-11-01", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 54, "location_summary": "Chandler, Arizona • Glendale, Arizona • Beverly Hills, California + 50 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Gilroy", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218516" }, { "nct_id": "NCT00318370", "title": "Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Farletuzumab", "type": "DRUG" }, { "name": "Chemo Plus Far", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 58, "start_date": "2006-05", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2015-09-09", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 18, "location_summary": "San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Covington", "state": "Louisiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Metarie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00318370" }, { "nct_id": "NCT02357147", "title": "Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma, Malignant" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Amatuximab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 124, "start_date": "2015-11-03", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 7, "location_summary": "La Jolla, California • Newark, Delaware • Bethesda, Maryland + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02357147" }, { "nct_id": "NCT00738699", "title": "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "MORAb-003 (farletuzumab)", "type": "DRUG" }, { "name": "0.9% Saline", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 415, "start_date": "2008-09", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2017-03-30", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 34, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738699" }, { "nct_id": "NCT01521325", "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma", "Pancreatic Cancer", "Ovarian Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Amatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-09", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01521325" }, { "nct_id": "NCT01748721", "title": "MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Hairy Cell Leukemia", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "anti-endosialin/TEM1 monoclonal antibody MORAb-004", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "13 Months to 21 Years" }, "enrollment_count": 27, "start_date": "2013-11", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2016-01-08", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01748721" }, { "nct_id": "NCT01507545", "title": "Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "MORAb-004", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best supportive care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2012-03-27", "completion_date": "2013-10-20", "has_results": true, "last_update_posted_date": "2022-05-06", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 67, "location_summary": "Alhambra, California • Bakersfield, California • Burbank, California + 54 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01507545" }, { "nct_id": "NCT00849667", "title": "Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Farletuzumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Taxane", "type": "DRUG" }, { "name": "Farletuzumab-matched placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1100, "start_date": "2009-04-16", "completion_date": "2013-04-12", "has_results": true, "last_update_posted_date": "2022-12-30", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849667" }, { "nct_id": "NCT00738582", "title": "An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "MORAb-009 (Amatuximab)", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Morphotek", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2008-12-31", "completion_date": "2014-01-10", "has_results": true, "last_update_posted_date": "2022-09-22", "last_synced_at": "2026-09-25T23:09:20.999Z", "location_count": 12, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738582" } ] }